Role of angiotensin II in liver fibrosis‐induced portal hypertension and therapeutic implications

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Hepatology Research

• Publication date

  2010-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1872-034X.2009.00581.xPMID 19737316
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Renal fibrosis

  2010cited by this paper
• Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease

  2009cited by this paper
• The effect of angiotensin‐blocking agents on liver fibrosis in patients with hepatitis C

  2009cited by this paper
• Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis

  2009cited by this paper
• Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat

  2009cited by this paper
• Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.

  2008cited by this paper
• Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications

  2008cited by this paper
• Cytokines and renin-angiotensin system signaling in hepatic fibrosis.

  2008cited by this paper
• Complications of Cirrhosis

  2008cited by this paper
• Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases.

  2007cited by this paper
• Transforming growth factor-β and fibrosis

  2007cited by this paper
• Transforming growth factor-beta and fibrosis.

  2007cited by this paper
• Molecular mechanisms of hepatic fibrogenesis

  2007cited by this paper
• The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7).

  2007cited by this paper
• AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers.

  2007cited by this paper
• Angiotensin II type 1 receptor blockade in early cirrhosis.

  2007cited by this paper
• Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension.

  2006cited by this paper
• Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.

  2006cited by this paper
• A pilot study in patients with established advanced liver fibrosis using pirfenidone

  2006cited by this paper
• Effects of perindopril and valsartan on expression of transforming growth factor‐β‐Smads in experimental hepatic fibrosis in rats

  2006cited by this paper
• Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice.

  2005cited by this paper
• Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2

  2005cited by this paper
• Liver fibrosis.

  2005cited by this paper
• Nonalcoholic fatty liver disease

  2005cited by this paper
• Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C

  2005cited by this paper
• Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct–ligated rats

  2005cited by this paper
• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

  2004cited by this paper
• Liver fibrosis

  2004cited by this paper
• Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function

  2003cited by this paper
• Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II.

  2003cited by this paper
• Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis

  2003cited by this paper
• Interferon alfa down‐regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice

  2003cited by this paper
• Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity

  2003cited by this paper
• Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development.

  2003cited by this paper
• Angiotensin II stimulates the nuclear translocation of Smad2 and induces PAI-1 mRNA in rat hepatic stellate cells.

  2003cited by this paper
• Cardiac Angiotensin II Type 2 Receptor Activates the Kinin/NO System and Inhibits Fibrosis

  2003cited by this paper
• Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C

  2002cited by this paper
• Literature alert

  2002cited by this paper
• Hypoxia‐induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis

  2002cited by this paper
• The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.

  2001cited by this paper
• Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

  2001cited by this paper
• Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats

  2001cited by this paper
• Angiotensin II and renal fibrosis.

  2001cited by this paper
• Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells.

  2001cited by this paper
• Transforming growth factor β signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis.

  2000cited by this paper
• Hepatitis C--global prevalence (update).

  2000cited by this paper
• Angiotensin II Activates Collagen I Gene Through a Mechanism Involving the MAP/ER Kinase Pathway

  2000cited by this paper
• Angiotensin II induces contraction and proliferation of human hepatic stellate cells.

  2000cited by this paper
• Complications of cirrhosis. I. Portal hypertension.

  2000cited by this paper
• Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis

  2000cited by this paper
• Hepatitis C--global prevalence (update).

  1999cited by this paper
• Effect of losartan, an Angiotensin II receptor antagonist, on portal pressure in cirrhosis

  1999cited by this paper
• Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling

  1997cited by this paper
• Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling.

  1997cited by this paper
• Counterregulatory actions of angiotensin-(1-7).

  1997cited by this paper
• Tissue repair and angiotensin II generated at sites of healing

  1997cited by this paper
• Angiotensin receptors and their antagonists.

  1996cited by this paper
• Pattern of sodium handling and its consequences in patients with preascitic cirrhosis.

  1995cited by this paper
• Propranolol plus isosorbide‐5‐mononitrate for portal hypertension in cirrhosis: Long‐term hemodynamic and renal effects

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• Renin-angiotensin system : a dual tissue and hormonal system for cardiovascular control

  1992cited by this paper
• Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure

  1992cited by this paper
• Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group.

  1991cited by this paper
• Ito‐cell gene expression and collagen regulation

  1990cited by this paper
• Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage.

  1990cited by this paper
• Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver.

  1988cited by this paper
• Nonalcoholic fatty liver disease.

  1986cited by this paper
• Effect of angiotensin‐ll blockade on systemic and hepatic haemodynamics and on the renin‐angiotensin‐aldosterone system in cirrhosis with ascites

  1981cited by this paper

• Iridoids in liver diseases: Mechanistic insights and molecular mechanism.

  2026cites this paper
• Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review

  2026cites this paper
• Aqueous Fraction from Cucumis sativus Aerial Parts Attenuates Angiotensin II-Induced Endothelial Dysfunction In Vivo by Activating Akt

  2023cites this paper
• Hepatoprotective effect of hydroalcoholic extract from root of Sechium edule (Jacq.) Sw. over hepatic injury induced by chronic application of angiotensin II

  2022cites this paper
• Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis

  2022cites this paper
• Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options

  2021cites this paper
• Protective effect of recombinant Lactobacillus plantarum against H2O2-induced oxidative stress in HUVEC cells

  2021cites this paper
• Role of the posterior mucosal defense barrier in portal hypertensive gastropathy.

  2021cites this paper
• World Journal of Gastroenterology From to of via the gut-liver-brain axis in

  2020cites this paper
• Cirrhotic portal hypertension: From pathophysiology to novel therapeutics

  2020cites this paper
• Characterization of a murine model of endothelial dysfunction induced by chronic intraperitoneal administration of angiotensin II

  2020cites this paper
• Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

  2019cites this paper
• Antiangiogenic Therapy for Hepatocellular Carcinoma

  2017cites this paper
• Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B

  2017cites this paper
• Treatment of Nonalcoholic Fatty Liver Disease: Where do we Stand? An Overview

  2016cites this paper
• Mechanisms of adaptation of the hepatic vasculature to the deteriorating conditions of blood circulation in liver cirrhosis.

  2016cites this paper
• The IL-24 gene protects human umbilical vein endothelial cells against H2O2-induced injury and may be useful as a treatment for cardiovascular disease

  2016cites this paper
• Epigallocatechin-3-gallate inhibits angiotensin II-induced C-reactive protein generation through interfering with the AT1-ROS-ERK1/2 signaling pathway in hepatocytes

  2016cites this paper
• [Morphofunctional rearrangement of the hepatic vasculature in the pathogenesis of portal hypertension in liver cirrhosis].

  2014cites this paper
• Differential gene expression profiles in spontaneously hypertensive rats induced by administration of enalapril and nifedipine.

  2013cites this paper
• Treatment of the Liver Cirrhosis: Modern Principles, Considering Syntropic Co- and Multimorbid Lesions of Other Organs and Systems of Organs

  2013cites this paper
• Molecular recognition of human angiotensin-coverting enzyme I (hACE I) and different inhibitors.

  2013cites this paper
• Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress.

  2012cites this paper
• Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.

  2012cites this paper